PT Diagnos Laboratorium Utama Tbk (DGNS) is a Jakarta-based healthcare-laboratory services company listed on the Indonesia Stock Exchange, not a U.S. exchange-traded fund. Because its shares are quoted in Indonesian rupiah (IDR), all figures below are in rupiah. The question of whether the stock can reach Rp350 is best approached as a technical and valuation discussion rather than a consensus forecast, because this micro-cap has essentially no sell-side analyst coverage.
DGNS is a small, thinly covered company, and no current analyst price targets attributable to named firms could be verified. Rather than fabricate a consensus, the Rp350 figure is a fallback objective resting on an identifiable technical milestone. The stock's 52-week high of roughly Rp382, set in February 2026, is the most concrete level traders and market commentators point to when discussing upside. Rp350 sits below that high but above the current price and is also a clean psychological round number that has functioned as a reference point during the stock's rallies. It should be read as a technical price objective discussed in public commentary, not as a brokerage price forecast.
With the stock recently trading near Rp280 to Rp290, a move to Rp350 implies an advance of about 20% to 25%. That qualifies as a substantial move by percentage terms and is not a trivial re-rating. The fundamental path is narrow. The company reported full-year 2025 sales of about Rp166.6 billion, a modest rise from roughly Rp163.1 billion a year earlier, while net income improved to about Rp2.9 billion from Rp747 million. That is encouraging directionally, but net margin is only around 1.8%, and the P/E (price-to-earnings) ratio of 80x to 150x reflects how little profit supports the current share price. To justify Rp350, the market would likely need to see sustained revenue growth and a clearer return to profitability after quarterly EPS turned negative in the first half of 2026.
The chart shows a stock still recovering from a steep multi-year decline from its July 2021 all-time high near Rp1,485. Recent consolidation around Rp220 provided a base before the rebound toward Rp280 to Rp290. On the downside, key support sits near Rp220, with the 52-week low near Rp136 as a deeper floor. On the upside, Rp300 is a psychological resistance level, followed by the Rp350 objective and then the 52-week high of about Rp382. A sustained close above Rp300 would be an important step toward testing Rp350, while a break back below Rp220 would undermine the recovery narrative.
Unlike a 12-month analyst target, a technical objective such as Rp350 carries no fixed time horizon. Investors should monitor quarterly earnings and whether EPS returns to positive territory, the use and impact of the private-placement proceeds, any further share issuance or shareholder transactions, and any exchange regulatory attention to unusual trading. Healthcare demand trends in Indonesia and the company's progress in genomics and homecare services are also relevant to whether the stock can sustain a move toward Rp350.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor open positions, and identify shifting trends more efficiently than manual screening alone. For a volatile, low-coverage name such as DGNS, automated signal monitoring can be a useful complement to fundamental research, though no signal is a substitute for independent judgment. Traders can explore the feature to see how it applies to their watchlists.
Can DGNS reach Rp350? The level represents a technical objective of roughly 20% to 25% above the recent price, grounded in the stock's 52-week high of Rp382 rather than in any analyst consensus. The strongest supports are revenue growth, a return to annual profitability in 2025, and fresh capital from a private placement. The principal obstacles are thin and volatile earnings, shareholder dilution, a demanding valuation, and the stock's history of sharp swings. Because no credible analyst target range exists, investors should treat Rp350 as a technical reference point, not a forecast, and watch earnings, dilution, and the key technical levels near Rp220 and Rp300 for direction.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.